Treating tuberculosis with spectinamides
Nature Medicine
2014년1월27일
Variations on an old drug generate promising clinical candidates for tuberculosis treatment, reports a study published this week in Nature Medicine. The work, done in mice, validates efforts to repurpose and modify existing drugs to increase their antibacterial efficacy.
Spectinomycin is a naturally found product that acts as an antibiotic, binding to bacterial ribosomes and blocking bacterial protein synthesis; however, it has only modest activity against Mycobacterium tuberculosis. Richard Lee and colleagues synthetically modified spectinomycin to create new drugs called spectinamides, which could potently inhibit M. tuberculosis growth in culture and in infected mice. These drugs selectively inhibited mycobacterial protein synthesis-sparing eukaryotic ribosomes-and avoided removal from the cell by a key drug transporter, thereby increasing mycobacterial killing activity.
doi: 10.1038/nm.3458
리서치 하이라이트
-
7월1일
Criminology: Predicting police enforcement bias in major US citiesNature Human Behaviour
-
7월1일
Space health: The path of most resistance could help limit bone loss during spaceflightScientific Reports
-
6월30일
Microbiology: Transmission of gastrointestinal viruses in salivaNature
-
6월29일
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
-
6월24일
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
6월23일
Scientific community: Women credited less than men in scientific paper authorshipNature